75 patents
Page 4 of 4
Utility
Intercourse assistance device
4 May 20
An intercourse assistance device for reducing the length of a penis that enters a vagina.
Julie Fryman, Michelle Larue
Filed: 19 Dec 17
Utility
Methods and compositions for treatment of epileptic disorders
30 Mar 20
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Matthew During
Filed: 19 Jun 19
Utility
Use of Gaboxadol for the Treatment of Tourette Syndrome, Tics and Stuttering
25 Mar 20
Treatment of Tourette syndrome using gaboxadol or a pharmaceutically acceptable salt thereof is provided.
Matthew DURING
Filed: 19 Sep 19
Utility
Methods of Treating Seizure Disorders and Prader-willi Syndrome
1 Jan 20
Methods of treating a seizure disorder with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided.
Matthew DURING
Filed: 7 Feb 18
Utility
Methods of Treating Developmental Disorders And/or Seizure Disorders with Etifoxine
1 Jan 20
Methods of treating developmental disorders and/or seizure disorders with etifoxine, a deuterated analog of etifoxine, or a pharmaceutically acceptable salt, solvate, or prodrug thereof are provided.
Matthew DURING
Filed: 12 Aug 19
Utility
Use of MIR-92A or MIR-145 In the Treatment of Angelman Syndrome
18 Dec 19
Expression of micoRNAs that negatively regulate the activity of the SNHG14 gene for can be used in treatment of Angelman Syndrome.
Matthew DURING
Filed: 13 Jun 19
Utility
Use of (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC Acid and Related Compounds, (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC Acid and Vigabatrin In the Treatment of Developmental Disorders
11 Dec 19
Methods and compositions for use treating Fragile X syndrome, Angelman syndrome, Fragile X-associated tremor/ataxia syndrome, Autism Spectrum Disorder, Asperger's syndrome, Pervasive developmental disorder not otherwise characterized, Childhood Disintegrative Disorder, Williams syndrome, or Jacobsen syndrome with a compound of Formula 1 as described herein, (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid, or vagabatrin, or pharmaceutically acceptable salts of any of the foregoing, are provided.
Matthew DURING, Brett ABRAHAMS
Filed: 6 Jun 19
Utility
Methods of treating behavioral syndromes using pipradrol
2 Dec 19
Methods of treating behavioral syndromes by administering a pharmaceutical composition of pipradrol or a pharmaceutically acceptable salt thereof are provided.
Matthew During
Filed: 7 Nov 18
Utility
Methods of Treating Attention Deficit Hyperactivity Disorder
20 Nov 19
Methods and compositions for treating Attention-deficit/hyperactivity disorder are provided which include administering to a patient in need thereof captodiamine or a pharmaceutically acceptable salt thereof.
Matthew During
Filed: 16 May 19
Utility
Methods of Treating Developmental Disorders And/or Seizure Disorders with Flupirtine
30 Oct 19
Methods of treating developmental disorders and/or seizure disorders with flupirtine or a pharmaceutically acceptable salt thereof are provided.
Matthew DURING
Filed: 19 Jun 19
Utility
Use of Gaboxadol In the Treatment of Substance Use Disorders
23 Oct 19
Methods of using gaboxadol or a pharmaceutically acceptable salt thereof and compositions of gaboxadol or a pharmaceutically acceptable salt thereof for use in treating a substance use disorder, preventing a substance use craving, diminishing a substance use craving, and/or facilitating substance use cessation are provided.
Matthew During
Filed: 5 Apr 19
Utility
Methods of Treating Developmental Disorders with Gaboxadol
23 Oct 19
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided.
Matthew DURING
Filed: 24 Jun 19
Utility
Methods and Compositions for Treatment of Epileptic Disorders
9 Oct 19
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Matthew DURING
Filed: 19 Jun 19
Utility
Use of (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC Acid and (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC Acid In the Treatment of Eye Disorders
2 Oct 19
Methods of treating eye disorders with (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid are provided.
Matthew During
Filed: 28 Mar 19
Utility
Methods of treating developmental disorders with biguanides
30 Sep 19
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Landau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, a seizure disorder and/or Williams Syndrome with a biguanide such as metformin, buformin, phenformin or a pharmaceutically acceptable salt thereof are provided.
Matthew During
Filed: 10 Oct 18